Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device ... ( PT. RICHMOND Calif. Jan. 29 /- Tr...)

HOME >> MEDICINE >> NEWS

Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

Date:1/29/2008

PT. RICHMOND, Calif., Jan. 29 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President & Chief Executive Officer, will present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference at the Grand Hyatt Hotel in New York City on Tuesday, February 5, 2008 at 8:40 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to file an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 has completed a successful dose ranging trial for the treatment of alcohol use disorder and a full clinical development program has begun. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
2. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
5. Amylin Pharmaceuticals Reports 2007 Financial Results
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries

Post Your Comments:

(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...

(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...

(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...

(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...

(Date:4/17/2014)... D.C. -- The world is less than 40 years ... implications for people and governments, according to a top ... the first time in human history, food production will ... of land, water and energy," said Dr. Fred Davies, ... security. "Food issues could become as politically destabilizing by ...

Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2 Health News:Is Parkinson's an autoimmune disease? 2 Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2 Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3 Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2 Health News:Food shortages could be most critical world issue by mid-century 2

[0] Building 'smart' cell-based therapies [0] Is Parkinson's an autoimmune disease?[0] Re-emergence of Ebola focuses need for global surveillance strategies [0] Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum [0] Food shortages could be most critical world issue by mid-century

... conducted this study which was self funded. The sweetness ... of the sweetener. // The researchers questioned about 30 ... sweeteners and sweet substances. This was done to detect ... with each substance. Sugar was rated highest. Participants found ...

... with fish oil supplements in teenagers.,Durham County Council’s senior ... 25 teenagers who had been rated with moderate to ... omega-3 fish and omega-6 evening primrose oil over a ... students aged 12 to 15 also had a high ...

... Prime Minister, Shaukat Aziz has been urged by the Poultry ... the poultry industry//. The industry is under crisis over the ... flu scare and the earthquake that hit the country on ... President of the Lahore Chamber of Commerce and Industry (LCCI) ...

... developed at Leeds that will benefit at large in ... the next generation// of miniaturized computers. ,By suspending ... and Dr Yulong Ding have created ‘nanofluids’ which can ... In a central heating system, nanofluids could increase efficiency ...

... Court, would ensure that patients or their relatives would be ... demand. Until now, patients and family members have been facing ... doctor or hospital as they tend to treat it as ... it is their property and therefore refuse to give the ...

... jointly by University of California, Berkeley, and Chilean researchers says ... in drinking water are more likely to succumb to lung ... in their adult life. ,It was found that ... than normal if the child's mother also drank the arsenic-contaminated ...

Cached Medicine News:Health News:Sweet, Sweeter and Sweetest 2 Health News:Poultry Industry Of Pakistan Stresses On Need Of Relief Package 2 Health News:Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life 2

Sweet, Sweeter and Sweetest Improvements in ADHD with Fish Oil Poultry Industry Of Pakistan Stresses On Need Of Relief Package Potential Benefits Of New Nanotechnology Patients Have Right To Access Medical Case Papers: Bombay High Court Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life

(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer. Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...

(Date:1/15/2014)... Jan. 15, 2014 According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...

(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...

[0] Tegra Medical Appoints New Chief Executive Officer [0] US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 [0] Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users

... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, oncology, dermatology, ... of patient dosing for a Phase 1 clinical ... human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) ...

... (Nasdaq: ALXA ) today announced positive results ... loxapine). This Phase 3,clinical trial was conducted in ... 5 mg and 10 mg doses of AZ-004 met ... significant reduction in,agitation from baseline to the 2-hour post-dose ...

Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....

The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....

Medicine Products:

Optima III 45 Noninsulated Retracting Grasper, with racthet Optima III Noninsulated Babcock Grasper, without ratchet Optima III Noninsulated Retraction Grasper, with ratchet Optima III Noninsulated Duck-Bill Grasp, without ratchet